Dr. Reddy's, Galena Biopharma to develop breast cancer vaccine

Dr. Reddy's Laboratories and US-based biopharmaceutical company Galena Biopharma announced on Wednesday, that they have entered into a development and commercialisation partnership to develop and commercialise the drug NeuVax (nelipepimut-S) in India .

It is a vaccine aimed at preventing the recurrence of breast cancer in patients under remission.

Under the agreement, Galena has licensed commercial rights to Dr. Reddy's for NeuVax in breast cancer as well as gastric cancers. Dr. Reddy's will lead the development of NeuVax in gastric cancer, and thus help expand the scope of the therapy.  Galena will receive "development and sales milestones, as well as double-digit royalties on net sales."

G V Prasad, Chairman and CEO, Dr. Reddy's says, "The partnership accelerates our strong commitment to innovation and efforts to bring newer options for cancer patients.... We believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer."